Illumina, a major vendor of DNA sequencing services to enable clinicians and researchers to read and understand genetic variations, is teaming up with IBM and Philips in separate genomic research projects.

IBM will integrate its Watson for Genomics decision support product, based on technology from Quest Diagnostics, with Illumina’s solid tumor profiling panel that can present a set of variants across 170 different types of genes to aid in development of personalized treatment options for cancer patients.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access